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ttp://dx.doi.org/10.1016/j.ajpath.2016.03.004Evidence suggests that activation of pancreatic endoplasmic reticulum kinase (PERK) signaling in
response to endoplasmic reticulum stress negatively or positively inﬂuences cell transformation by
regulating apoptosis. Patched1 heterozygous deﬁcient (Ptch1þ/) mice reproduce human Gorlin’s
syndrome and are regarded as the best animal model to study tumorigenesis of the sonic hedgehog
subgroup of medulloblastomas. It is believed that medulloblastomas in Ptch1þ/ mice results from the
transformation of granule cell precursors (GCPs) in the developing cerebellum. Here, we determined the
role of PERK signaling on medulloblastoma tumorigenesis by assessing its effects on premalignant GCPs
and tumor cells. We found that PERK signaling was activated in both premalignant GCPs in young
Ptch1þ/ mice and medulloblastoma cells in adult mice. We demonstrated that PERK haploinsufﬁciency
reduced the incidence of medulloblastomas in Ptch1þ/ mice. Interestingly, PERK haploinsufﬁciency
enhanced apoptosis of premalignant GCPs in young Ptch1þ/ mice but had no signiﬁcant effect on
medulloblastoma cells in adult mice. Moreover, we showed that the PERK pathway was activated in
medulloblastomas in humans. These results suggest that PERK signaling promotes medulloblastoma
tumorigenesis by attenuating apoptosis of premalignant GCPs during the course of malignant trans-
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in response to endoplasmic reticulum (ER) stress promotes
cell survival under stressful conditions through inhibition of
global protein biosynthesis and induction of certain stress-
induced cytoprotective genes by phosphorylating translation
initiation factor 2a (eIF2a).1,2 Nevertheless, PERK activa-
tion also controls an apoptotic program to eliminate ER-
stressed cells.3,4 Studies found that PERK activation
induced by hypoxia and nutritional deﬁciency, hallmarks of
the solid tumor microenvironment, inﬂuences tumor devel-
opment by regulating tumor cell viability, tumor invasion, and
angiogenesis.5e8 However, because of the double-edged
sword nature of PERK signaling, the data about its role, pro-
moting or inhibiting, in tumor development are contradic-
tory.9,10 It is well documented that apoptosis serves as a natural
barrier to malignant transformation. Cell transformationstigative Pathology. Published by Elsevier Inc
Y license (http://creativecommons.org/licensesrequires concomitant activation of unrestricted cell prolifera-
tion and suppression of apoptosis.11,12 Interestingly, recent
reports suggest that PERK signaling participates in cell
transformation by regulating apoptosis.13,14 A report found
that PERK activation promotes Myc-dependent malignant
transformation by attenuating cell apoptosis.13 In contrast,
another report found that PERK activation suppresses malig-
nant transformation by enhancing cell apoptosis.15
Medulloblastoma is the most common solid malignancy of
childhood.16 From gene expression proﬁling, medulloblastoma.
/by/4.0).
Ho et alcan be divided into four discrete molecular subgroups: sonic
hedgehog (SHH) subgroup, WNT subgroup, subgroup 3,
and subgroup 4.17,18 Although multiple genetic mutations
that drive sustained cell proliferation are documented in
medulloblastoma,17e19 the mechanisms that regulate cell
apoptosis during malignant transformation remain unclear.
Mice heterozygous for Patched1 (Ptch1þ/), a SHH receptor,
recapitulate human Gorlin’s syndrome and are regarded as
the best animal model to study tumorigenesis of the SHH
subgroup of medulloblastomas.20,21 Medulloblastoma in
Ptch1þ/ mice arises from granule cell precursors (GCPs) in
the external granular layer (EGL) of the developing cere-
bellum and shows distinct steps of progression.22e24 These
mice have hyperplastic lesions that contain premalignant
GCPs in the EGL as late as 6 weeks of age. Most hyperplastic
lesions regress; however, a few hyperplastic lesions undergo
malignant transformation and progress to medulloblastoma.
Mutations of Perk (also known as Eif2ak3) were observed
in human medulloblastoma. A report found that 7 of 35
human medulloblastomas exhibit Perk mutations.25 Our
previous in vitro study found that PERK activation facili-
tates human medulloblastoma cell migration and invasion
through induction of vascular endothelial growth factor A
(VEGF-A).26 The report also found that PERK inactivation
suppresses human medulloblastoma cell migration and in-
vasion.26 Moreover, a study found that ER stress responsive
genes are up-regulated in premalignant GCPs in young
Ptch1þ/ mice.22 Thus, we sought to elucidate the impact of
the PERK branch of the ER stress response on the devel-
opment of medulloblastoma. In this study, we conﬁrmed
PERK activation in human medulloblastoma and reported
that PERK activation facilitated medulloblastoma develop-
ment in Ptch1þ/ mice by attenuating premalignant GCP
apoptosis. PERK haploinsufﬁciency reduced the incidence of
medulloblastomas in Ptch1þ/ mice, which was associated
with increased apoptosis of premalignant GCPs in young
mice. Surprisingly, PERK haploinsufﬁciency had a minimal
effect on medulloblastoma cells in adult Ptch1þ/ mice.
Materials and Methods
Generation of Mice
Ptch1þ/ mice20 on a mixed C57BL/6  129Sv background
were purchased from The Jackson Laboratory (Bar Harbor,
ME). Ptch1þ/ mice were crossed with Perk heterozygous
deﬁcient (Perkþ/) mice27 on the C57BL/6 background to
obtain Ptch1þ/; Perkþ/þ mice and Ptch1þ/; Perkþ/
mice. Genotypes were determined by PCR from the DNA
extracted from tail tips. The following primers were used for
PCR ampliﬁcation: PJ1 (50-ACAAGAAAGCAGAGTCC-
GGG-30) and PJ2 (50-GTCACGACGTTGTAAAACGAC-30)
for Ptch1þ/ mice genotyping; 1740S (50-AAGGACCCT-
ATCCTCCTGCTGCAC-30), PGK.255R (50-GCTACCGGT-
GGATGTGGAATGTG-30), and i.6AS (50-CGGAGACAG-
TACAAGCGCAGATGA-30) for Perkþ/ mice genotyping.1940Mice were monitored daily to detect medulloblastoma phe-
notypes, including ataxia, decreased movement, poor
grooming, and doming of the skull, until the age of 8 months.
All animal procedures were conducted in complete compli-
ance with the NIH’s Guide for the Care and Use of Labo-
ratory Animals28 and were approved by the Institutional
Animal Care and Use Committee of the University of
Minnesota.
Histology, Immunohistochemistry, and TUNEL Staining
Adult mice with medulloblastoma phenotypes and all
8-month-old asymptomatic mice received an intraperitoneal
injection of 100 mg/kg bromodeoxyuridine (BrdU; Sigma-
Aldrich, St. Louis, MO) 2 hours before perfusion. Six-week-
old asymptomatic mice received a BrdU injection 8 hours
before perfusion. Anesthetized mice were perfused through
the left cardiac ventricle with 4% paraformaldehyde in 0.1
mol/L phosphate buffer. Brains were bisected in the sagittal
plane, and one-half was postﬁxed for at least 48 hours in 4%
paraformaldehyde in phosphate-buffered saline, dehydrated
through graded alcohols, and embedded in parafﬁn. Serial
sections of 5-mm thickness were cut, and every 10th section
in the series was routinely stained with hematoxylin and
eosin (H&E). The other half of the brain was postﬁxed for 1
hour in 4% paraformaldehyde in phosphate-buffered saline,
cryopreserved in 30% sucrose for 48 hours, embedded in
OCT compound, and frozen on dry ice. Frozen sections
were cut in a cryostat at 10-mm thickness. Immunohisto-
chemistry (IHC) for NeuN (dilution 1: 200; Millipore,
Temecula, CA), proliferating cell nuclear antigen (PCNA;
dilution 1:50,000; Sigma-Aldrich), phosphorylated PERK
(p-PERK; dilution 1:100; Santa Cruz Biotechnology, Santa
Cruz, CA), glial ﬁbrillary acidic protein (dilution 1:1000;
Covance, Princeton, NJ), synaptophysin (dilution 1:200;
Millipore), VEGF-A (dilution 1:50; Santa Cruz Biotech-
nology), active-caspase 3 (dilution 1:200; Cell Signaling
Technology, Danvers, MA), p53 (dilution 1:100; Santa
Cruz Biotechnology), and p53 up-regulated modulator of
apoptosis (PUMA; dilution 1:100; Santa Cruz Biotech-
nology) were performed on parafﬁn sections. IHC for CD31
(dilution 1:50; Santa Cruz Biotechnology) was performed
on cryosections. All primary antibodies, with the exception
of p53 and PUMA antibodies, were detected with the
Vectastain ABC kits (Vector Laboratories, Burlingame, CA)
and 3050-diaminobenzidine/H2O2 reagent (Vector Labora-
tories) as substrate. p53 and PUMA antibodies were
detected with the ﬂuorescein-labeled secondary antibody
(Vector Laboratories). Fluorescent-stained sections were
mounted with Vectashield mounting medium with DAPI
(Vector Laboratories) and visualized with the Zeiss Axi-
oskop 2 microscope (Carl Zeiss GmbH, Jena, Germany).
Terminal deoxynucleotidyl transferaseemediated bio-
tinylated UTP nick end labeling (TUNEL) staining was
performed on parafﬁn sections with the use of the ApopTag
kit (Millipore) according to the manufacturer’s instructions.ajp.amjpathol.org - The American Journal of Pathology
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formed on parafﬁn sections as described previously.29,30 We
quantiﬁed positive cells for BrdU, TUNEL, and VEGF-A
and for CD31þ blood vessels in the center of medullo-
blastoma or hyperplastic lesions in the cerebellum as
described previously.29,30
Western Blot Analysis
Cerebellar tissues were removed from adult control wild-type
(WT) mice and adult symptomatic Ptch1þ/; Perkþ/þ mice
and Ptch1þ/; Perkþ/ mice, which displayed typical me-
dulloblastoma clinical phenotypes and enlarged cerebellum.
These tissues were homogenized in 5 volumes of Triton X-
100 buffer with the use of a motorized homogenizer as pre-
viously described.31e33 After incubation on ice for 15 mi-
nutes, the extracts were cleared by centrifugation at 18,000 g
for 30minutes twice. The protein concentration of each extract
was determined by DC Protein Assay (Bio-Rad Laboratories,
Hercules, CA). The extracts (120 mg) were separated by SDS-
PAGE and transferred to nitrocellulose membranes. The blots
were then incubated with primary antibodies to p-PERK
(dilution 1:1000; Santa Cruz Biotechnology), p-eIF2a (dilu-
tion 1:1000; Cell Signaling Technology), eIF2a (dilution
1:1000; SantaCruzBiotechnology), and actin (dilution 1:5000;
Sigma-Aldrich), followed by the horseradish peroxidase-
conjugated secondary antibody (Vector Laboratories). The
chemiluminescent signal was detected by the ECL Detection
Reagents (GE Healthcare Biosciences, Piscataway, NJ). The
intensity of the recorded chemiluminescence signal was
quantiﬁed with the ImageQuantTL LAS4000 software version
1.2 from GE Healthcare Life Sciences.
TaqMan Real-Time PCR
Cerebellar tissueswere removed fromadult controlWTmice and
adult symptomatic Ptch1þ/; Perkþ/þ mice and Ptch1þ/;
Perkþ/mice, which displayed typical medulloblastoma clinical
phenotypes and enlarged cerebellum.RNAwas isolated from the
cerebellumwith the use of TRIzol reagent (Invitrogen, Carlsbad,
CA) and was treated with DNase I (Invitrogen) to eliminate
genomic DNA. Reverse transcription was performed with the
iScript cDNA Synthesis Kit (Bio-Rad Laboratories). TaqMan
real-time PCR was performed with iQ Supermix (Bio-Rad Lab-
oratories) on the LightCycler 480 System (Roche Diagnostics
Corporation, Indianapolis, IN) as described previously.26,29,31
Human Medulloblastoma Samples and IHC
Parafﬁn-embedded human medulloblastoma sections (5-mm
thickness) and brain sections from individuals without brain
tumor were provided by Brain Tumor Tissue Bank (London,
ON, Canada), including six cases of pediatric medulloblas-
toma, three cases of adult medulloblastoma, and three
nontumor brain tissue samples. IHC for p-PERK and CAATT
enhancer binding protein homologous protein (CHOP;The American Journal of Pathology - ajp.amjpathol.orgdilution 1:100; Thermo Scientiﬁc, Grand Island, NY) was
performed as described in Histology, Immunohistochemistry,
and TUNEL Staining. The degree of positive staining for
p-PERK was determined by using a semiquantitative staining
indexZ intensity distribution. The intensity of cytoplasmic
staining detected by IHC was scored on a scale of 0 to 4:
0 Z negative staining, 1 Z weak staining, 2 Z modest
staining, 3Zmoderate staining, and 4Z strong staining. The
distribution was scored on a scale of 1 to 4 from the percentage
of cells with any level of staining: 1 Z 1% to 25% positive
cells, 2 Z 26% to 50% positive cells, 3 Z 51% to 75%
positive cells, and 4Z 76% to 100% positive cells.
Statistical Analysis
Data are expressed as means  SD. Comparisons between
two groups were statistically evaluated by Student’s t-test
with the use of GraphPad Prism software version 6
(GraphPad Software Inc., La Jolla, CA). The incidence of
symptomatic medulloblastoma between Ptch1þ/; Perkþ/þ
mice and Ptch1þ/; Perkþ/ mice was statistically evaluated
by Kaplan-Meier analysis and the incidence of total me-
dulloblastoma between these two groups was statistically
evaluated by c2 test with the use of Prism 6 (GraphPad).
P < 0.05 was considered signiﬁcant.
Results
PERK Activation in Human Medulloblastoma
During ER stress, PERK is activated through oligomerization
and autophosphorylation, which coordinates an adaptive
program by phosphorylating eIF2a at serine 51.1 To assess
the potential relevance of previous observations of the
enhanced expression of ER stress responsive genes in mouse
models of medulloblastoma,22,29 we estimated the level of
PERK activity in human medulloblastoma by p-PERK IHC.
As expected, immunoreactivity of p-PERK was undetectable
in nontumor brain tissues (Figure 1A). Interestingly, a num-
ber of tumor cells were positive for p-PERK in clinical
samples of pediatric medulloblastoma (Figure 1B, Table 1),
and the p-PERK IHC signal was also markedly increased in
the tumor cells in adult medulloblastoma (Figure 1C,
Table 1). Moreover, semiquantitative analysis conﬁrmed that
PERK was activated in medulloblastoma in all six cases of
pediatric patients and three cases of adult patients (Table 1).
However, the intensity and distribution of p-PERK staining in
human medulloblastoma were variable, which likely reﬂects
the heterogeneity of human tumor. In addition, IHC for
CHOP, a PERK-responsive gene, found that immunoreac-
tivity of CHOP was undetectable in nontumor brain tissues
(Figure 1D), but it became detectable in a number of tumor
cells in both pediatric and adult medulloblastomas (Figure 1,
E and F). Taken together, our data suggest that PERK
signaling is enhanced in human medulloblastoma, prompting
an enquiry into its potential pathophysiologic signiﬁcance.1941
Figure 1 Activation of PERK signaling in
human medulloblastoma. A: p-PERK IHC found that
immunoreactivity of p-PERK was undetectable in
nontumor brain tissues. B: A representative image
from pediatric medulloblastoma 5 in Table 1 shows
that a number of tumor cells are positive for
p-PERK in pediatric medulloblastoma. C: A repre-
sentative image from adult medulloblastoma 1 in
Table 1 shows that the level of p-PERK is markedly
increased in the tumor cells in adult medulloblas-
toma. D: Immunoreactivity of CHOP was unde-
tectable in nontumor brain tissues. E: Many tumor
cells were positive for CHOP in pediatric medullo-
blastoma. F: Many tumor cells were positive for
CHOP in adult medulloblastoma. n Z 3 patients
(A, C, D, F); nZ 6 patients (B and E). Scale barZ
50 mm. CHOP, CAATT enhancer binding protein
homologous protein; IHC, immunohistochemistry;
p-, phosphorylated; PERK, pancreatic endoplasmic
reticulum kinase.
Ho et alPERK Activation in Medulloblastoma Cells in Adult
Ptch1þ/ Mice and in Premalignant GCPs in Young Mice
Medulloblastomas in Ptch1þ/ mice arises from the
cerebellar GCPs in the EGL.34,35 During early postnatal
development, GCPs proliferate, differentiate, and migrate
to their ﬁnal destination, the internal granule layer. In
normal mice, by postnatal day 21, this process is com-
plete, and there are no GCPs in the EGL. In contrast,
Ptch1þ/ mice have abnormal patches of premalignant
GCPs in the EGL of the cerebellum at the age of 3
weeks.22,36 By the age of 6 weeks, these mice have focal
hyperplastic lesions or diffuse hyperplastic lesions that
contain premalignant GCPs in the cerebellum. These
hyperplastic lesions either undergo malignant trans-
formation and progress to medulloblastoma or regress
over time.22,24,37 H&E staining revealed typical medul-
loblastoma in the cerebellum of adult Ptch1þ/ mice that
displayed medulloblastoma clinical phenotypes (Figure 2B)
and typical hyperplastic lesions in the EGL in the cerebellum
of 6-week-old Ptch1þ/ mice (Figure 2D) compared with
the normal cerebellum of age-matched WT mice (Figure 2, A
and C).Table 1 Semiquantitative Analysis of p-PERK IHC
Medulloblastoma
sample
Patient
age
Patient
sex
Staining
intensity
Staining
distribution
Pediatric 1 11 years Female 2 2
Pediatric 2 8 years Male 2 1
Pediatric 3 3 years Female 1 1
Pediatric 4 12 years Male 1 1
Pediatric 5 6 years Male 3 3
Pediatric 6 7 months Male 1 1
Adult 1 32 years Male 4 4
Adult 2 30 years Male 3 4
Adult 3 39 years Female 2 2
IHC, immunohistochemistry; p-PERK, phosphorylated pancreatic endo-
plasmic reticulum kinase.
1942To investigate the role of PERK signaling in medullo-
blastoma tumorigenesis, we determined the activity of PERK
signaling in medulloblastoma cells and premalignant
GCPs in Ptch1þ/ mice. Similar to our ﬁnding in human
medulloblastoma samples (see Perk Activation in Human
Medulloblastoma), p-PERK IHC found that the immunore-
activity of p-PERK was undetectable in cells in the cere-
bellumof adultWTmice (Figure 2E), but it became detectable
in a number of medulloblastoma cells in adult Ptch1þ/mice
(Figure 2F).Western blot analysis also found that the levels of
p-PERK and p-eIF2a were signiﬁcantly increased in the
cerebellum of adult Ptch1þ/ mice with medulloblastomas
compared with adult WT mice (Figure 2, I and J). Although
real-time PCR analysis found comparable levels of PERK
mRNA in the cerebellum of adult WT mice and Ptch1þ/
mice with medulloblastomas, the mRNA levels of CHOP and
growth arrest and DNA damage 34 (GADD34), target genes
of the PERK-eIF2a pathway, were signiﬁcantly increased in
the cerebellum of adult Ptch1þ/ mice with medulloblas-
tomas compared with adult WTmice (Figure 2K). Moreover,
consistent with a previous report indicating that the levels of
ER stress responsive genes were elevated in premalignant
GCPs in hyperplastic lesions in 6-week-old Ptch1þ/mice,22
p-PERK IHC found that the immunoreactivity of p-PERK
was undetectable in the cerebellar cells of 6-week-old WT
mice (Figure 2G) but became detectable in a number of pre-
malignant GCPs in hyperplastic lesions in Ptch1þ/ mice
(Figure 2H). Taken together, these data indicate that PERK
signaling is activated in both premalignant GCPs and
medulloblastoma cells in Ptch1þ/ mice, suggesting its
potential role in tumorigenesis.PERK Haploinsufﬁciency Reduces the Incidence of
Medulloblastomas in Ptch1þ/ Mice
Ptch1þ/ mice develop symptomatic medulloblastomas
typically between the ages of 8 and 35 weeks.21,38 Perkajp.amjpathol.org - The American Journal of Pathology
Figure 2 Activation of PERK signaling in both hyperplastic lesions and medulloblastomas in the cerebellum of Ptch1þ/ mice. AeD: H&E staining revealed
a normal cerebellum in adult WT mice (A), a medulloblastoma in the cerebellum of adult Ptch1þ/ mice (B), a normal cerebellum in 6-week-old WT mice (C),
and a hyperplastic lesion (arrow) in the cerebellar EGL of 6-week-old Ptch1þ/ mice (D). E and F: p-PERK IHC found that p-PERK is undetectable in cells in the
cerebellum of adult WT mice but became detectable in a number of cells in medulloblastomas in adult Ptch1þ/ mice. G and H: p-PERK IHC found that p-PERK
was undetectable in cells in the cerebellum of 6-week-old WT mice but became detectable in a number of cells in hyperplastic lesions in the cerebellar EGL of
6-week-old Ptch1þ/ mice. I and J: Western blot analysis found signiﬁcantly increased levels of p-PERK and p-eIF2a in the cerebellum of adult Ptch1þ/ mice
with medulloblastomas compared with adult WT mice. K: Real-time PCR analysis found that the mRNA level of PERK in the cerebellum of adult Ptch1þ/ mice
with medulloblastomas was comparable with adult WT mice and that the mRNA levels of CHOP and GADD34 were signiﬁcantly increased in the cerebellum of
adult Ptch1þ/ mice with medulloblastomas compared with adult WT mice. Data are expressed as means  SD. nZ 3 animals. *P < 0.05. Scale bars: 1000 mm
(AeD); 100 mm (EeH). CHOP, CAATT enhancer binding protein homologous protein; EGL, external granular layer; eIF2a, translation initiation factor 2a;
GADD34, growth arrest and DNA damage 34; H&E, hematoxylin and eosin; IHC, immunohistochemistry; p-, phosphorylated; PERK, pancreatic endoplasmic
reticulum kinase; WT, wild-type.
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Figure 3 PERK heterozygous deﬁciency
reduced the incidence of symptomatic medullo-
blastomas in Ptch1þ/ mice. The percentage of
mice that developed symptomatic medulloblas-
toma. n Z 57 animals. PERK, pancreatic endo-
plasmic reticulum kinase.
Ho et alhomozygous-deﬁcient mice die prematurely because of
progressive diabetes and exocrine pancreatic deﬁciency.27
Perk heterozygous-deﬁcient (Perkþ/) mice appear healthy
but display evidence of haploinsufﬁciency.32,39,40 Impor-
tantly, it was found that Perkþ/ mice do not display any
abnormalities in the central nervous system under normal
conditions.39e41 Therefore, we used Perkþ/ mice to
determine the impact of PERK signaling on medulloblas-
toma tumorigenesis in Ptch1þ/ mice. Ptch1þ/ mice were
crossed with Perkþ/ mice to obtain Ptch1þ/; Perkþ/þ
mice and Ptch1þ/; Perkþ/ mice. These mice were moni-
tored daily up to 8 months to detect medulloblastoma
phenotypes, including ataxia, decreased movement, poor
grooming, and doming of the skull. Medulloblastoma for-
mation in symptomatic mice was veriﬁed by gross exami-
nation, namely assessing enlargement of the cerebellum, and
by H&E staining. We found that the frequency of symp-
tomatic medulloblastomas in Ptch1þ/; Perkþ/ mice was
signiﬁcantly reduced compared with Ptch1þ/; Perkþ/þ
mice (8 of 57 Ptch1þ/; Perkþ/ mice versus 17 of 57
Ptch1þ/; Perkþ/þ mice; P Z 0.0375) (Figure 3). More-
over, necropsy was performed on all 8-month-old asymp-
tomatic Ptch1þ/; Perkþ/þ and Ptch1þ/; Perkþ/ mice.
Gross examination and H&E staining revealed that 3 of 49
asymptomatic Ptch1þ/; Perkþ/ mice and 3 of 40 asymp-
tomatic Ptch1þ/; Perkþ/þ mice had medulloblastomas,
respectively. Consistent with the previous studies,22,24 we did
not ﬁnd any hyperplastic lesions in the cerebellar EGL of
8-month-old Ptch1þ/; Perkþ/þ mice or Ptch1þ/; Perkþ/
mice. Thus, PERK heterozygous deﬁciency signiﬁcantly
decreased the incidence of medulloblastomas in Ptch1þ/
mice (11 of 57 Ptch1þ/; Perkþ/ mice versus 20 of 57
Ptch1þ/; Perkþ/þ mice; PZ 0.0457).
We further determined whether PERK heterozygous
deﬁciency impaired the activity of PERK signaling in me-
dulloblastoma cells in Ptch1þ/ mice. p-PERK IHC found
that the immunoreactivity of p-PERK was noticeably
decreased in medulloblastomas in Ptch1þ/; Perkþ/ mice
compared with Ptch1þ/; Perkþ/þ mice (Figure 4, C and D).
Moreover, Western blot analysis found that the levels of
p-PERK and p-eIF2a were signiﬁcantly decreased in the
cerebellum of Ptch1þ/; Perkþ/ mice with medulloblas-
tomas compared with Ptch1þ/; Perkþ/þ mice (Figure 4, E
and F). As expected, real-time PCR analysis found that
the level of PERK mRNA was reduced by approximately
one-half in the cerebellum of Ptch1þ/; Perkþ/ mice with1944medulloblastomas compared with Ptch1þ/; Perkþ/þ mice
(Figure 4G). Moreover, real-time PCR analysis found that
PERK heterozygous deﬁciency signiﬁcantly reduced the
expression of CHOP and GADD34 in the cerebellum
of Ptch1þ/ mice with medulloblastomas (Figure 4G).
Taken together, these results indicate that PERK hap-
loinsufﬁciency reduces the incidence of medulloblastomas
in Ptch1þ/ mice, likely through reduced PERK-mediated
eIF2a phosphorylation.
Next, we determined the effects of PERK hap-
loinsufﬁciency on cell proliferation, cell apoptosis, and
angiogenesis in medulloblastomas in Ptch1þ/ mice. H&E
staining indicated that the structural characteristics of me-
dulloblastomas in Ptch1þ/; Perkþ/ mice was comparable
with Ptch1þ/; Perkþ/þ mice (Figure 4, A and B). IHC for
glial ﬁbrillary acidic protein and synaptophysin found
that the expression pattern of both glial ﬁbrillary acidic
protein and synaptophysin in medulloblastomas in Ptch1þ/;
Perkþ/ mice was comparable with Ptch1þ/; Perkþ/þ mice
(Figure 5, AeD). BrdU labeling (Figure 5, E, F, and M) and
PCNA IHC (data not shown) found that PERK heterozygous
deﬁciency did not signiﬁcantly change the number of
proliferating cells in medulloblastomas in Ptch1þ/ mice.
Moreover, TUNEL staining found that PERK heterozygous
deﬁciency had no signiﬁcant effect on cell apoptosis in me-
dulloblastomas in Ptch1þ/ mice (Figure 5, G, H, and M). A
number of studies suggest that activation of PERK signaling
enhances angiogenesis in tumors, including medulloblas-
toma, by induction of VEGF-A.29,42 Surprisingly, VEGF-A
IHC found that PERK heterozygous deﬁciency did not
signiﬁcantly alter VEGF-A expression in medulloblastomas
in Ptch1þ/ mice (Figure 5, I, J, and M), and CD31 IHC
found that PERK heterozygous deﬁciency did not signiﬁ-
cantly change angiogenesis in this tumor (Figure 5, K, L,
and N). Collectively, these data suggest that PERK hap-
loinsufﬁciency has a minimal effect on cell proliferation,
cell apoptosis, and angiogenesis in medulloblastomas in
adult Ptch1þ/ mice. Thus, it is unlikely that PERK hap-
loinsufﬁciency impairs medulloblastoma formation in
Ptch1þ/ mice through its effects on tumor cells.
PERK Haploinsufﬁciency Increases Premalignant GCPs
Apoptosis in the Cerebellum of Young Ptch1þ/ Mice
Evidence is emerging that PERK signaling inﬂuences
tumorigenesis by regulating cell apoptosis during the courseajp.amjpathol.org - The American Journal of Pathology
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igenesis in the cerebellum of Ptch1þ/ mice found distinct
steps of progression; ﬁrst, focal hyperplastic lesions develop
in the EGL; second, diffuse hyperplastic lesions form in the
EGL and molecular layer; ﬁnally, medulloblastoma ari-
ses.23,24,37 Previous reports found that both focal hyperplastic
lesions and diffuse hyperplastic lesions can be observed in the
cerebellum of Ptch1þ/ mice as late as 6 weeks of age.22,24
The diffuse hyperplastic lesions are reversible and represent
the ﬁnal step in the process of malignant transformation, in
which premalignant GCPs either gain additional genetic
mutations or epigenetic changes to become irreversible tumor
cells, or undergo regression.24,37,44 Therefore, we determined
the effects of PERK haploinsufﬁciency on the proliferation
and apoptosis of premalignant GCPs in diffuse hyperplastic
lesions in the cerebellum of 6-week-old Ptch1þ/ mice.
We serially sectioned whole parafﬁn-embedded half-
cerebellum of 6-week-old mice, each half-cerebellum yielded
approximately 210 sections 5-mm thick. Every 10th section
in the series was either stained by H&E or immunostained
by the NeuN antibody or PCNA antibody. Focal hyper-
plastic lesions, which contained >10 premalignant GCPs
that were negative for NeuN (a marker of mature neurons)
and positive for PCNA, were observed in the cerebellum of
Ptch1þ/; Perkþ/þ mice (Supplemental Figure S1, A, C, and
E) and Ptch1þ/; Perkþ/ mice (Supplemental Figure S1, B,
D, and F). Moreover, both Ptch1þ/; Perkþ/þ mice and
Ptch1þ/; Perkþ/ mice had diffuse hyperplastic lesions in
the cerebellum (Supplemental Figure S1, GeL), which
contained a thick layer (>15 cell layers) of NeuN-negative
and PCNA-positive premalignant GCPs diffusing in the
EGL and molecular layer. We found, however, that the
number of total hyperplastic lesions in the cerebellum of
6-week-old Ptch1þ/; Perkþ/ mice was comparable with
Ptch1þ/; Perkþ/þmice (Figure 6A). Similarly, we found that
PERK heterozygous deﬁciency did not reduce the number of
diffuse hyperplastic lesions in the cerebellum of 6-week-old
Ptch1þ/ mice (Figure 6B and Figure 7, A and B).
p-PERK IHC found that immunoreactivity of p-PERK
was noticeably decreased in diffuse hyperplastic lesions inFigure 4 PERK heterozygous deﬁciency attenuated the activity of PERK
signaling in medulloblastomas in adult Ptch1þ/ mice. A and B: H&E
staining found that PERK heterozygous deﬁciency did not change the
structural characteristics of medulloblastomas in adult Ptch1þ/ mice. C
and D: p-PERK IHC found noticeably decreased immunoreactivity of p-PERK
in medulloblastomas in adult Ptch1þ/; Perkþ/ mice compared with
Ptch1þ/; Perkþ/þ mice. E and F: Western blot analysis found signiﬁcantly
decreased levels of p-PERK and p-eIF2a in the cerebellum of adult Ptch1þ/
; Perkþ/ mice with medulloblastomas compared with Ptch1þ/; Perkþ/þ
mice. G: Real-time PCR analysis found that the mRNA levels of PERK, CHOP,
and GADD34 were signiﬁcantly decreased in the cerebellum of Ptch1þ/;
Perkþ/ mice with medulloblastomas compared with Ptch1þ/; Perkþ/þ
mice. Data are expressed as means  SD. nZ 3 animals. *P < 0.05. Scale
bars: 1000 mm (A and B); 100 mm (C and D). CHOP, CAATT enhancer binding
protein homologous protein; eIF2a, translation initiation factor 2a;
GADD34, growth arrest and DNA damage 34; H&E, hematoxylin and eosin;
IHC, immunohistochemistry; p-, phosphorylated; PERK, pancreatic endo-
plasmic reticulum kinase.
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Figure 5 PERK heterozygous deﬁciency did not affect cell proliferation, cell apoptosis, or angiogenesis in medulloblastomas in adult Ptch1þ/ mice. A and B:
GFAP IHC found that PERK heterozygous deﬁciency did not change the expression pattern of GFAP in medulloblastomas in adult Ptch1þ/ mice. C and D:
Synaptophysin IHC found that PERK heterozygous deﬁciency did not change the expression pattern of synaptophysin in medulloblastomas in adult Ptch1þ/ mice.
E, F, and M: BrdU labeling revealed comparable number of proliferating cells in medulloblastomas in adult Ptch1þ/; Perkþ/þ mice and Ptch1þ/; Perkþ/ mice.
G, H, and M: TUNEL staining revealed comparable number of apoptotic cells in medulloblastomas in adult Ptch1þ/; Perkþ/þ mice and Ptch1þ/; Perkþ/
mice. I, J, and M: VEGF-A IHC revealed comparable number of VEGF-Aepositive cells in medulloblastomas in adult Ptch1þ/; Perkþ/þ mice and Ptch1þ/; Perkþ/
mice. K, L, and N: CD31 IHC revealed comparable number of blood vessels in medulloblastomas in adult Ptch1þ/; Perkþ/þ mice and Ptch1þ/; Perkþ/ mice. Data
are expressed as means  SD. nZ 4 animals. Scale bars: 50 mm (AeJ); 100 mm (K and L). BrdU, bromodeoxyuridine; CD31, cluster of differentiation 31; GFAP,
glial ﬁbrillary acidic protein; IHC, immunohistochemistry; PERK, pancreatic endoplasmic reticulum kinase; TUNEL, terminal deoxynucleotidyl transferasee
mediated biotinylated UTP nick end labeling; VEGF-A, vascular endothelial growth factor A.
Ho et al6-week-old Ptch1þ/; Perkþ/ mice compared with Ptch1þ/;
Perkþ/þ mice (Figure 7, C and D). BrdU labeling
(Figure 7, E, F, and K) and PCNA IHC (data not shown)
found that PERK heterozygous deﬁciency did not signiﬁ-
cantly alter the rate of cell proliferation in diffuse hyper-
plastic lesions in 6-week-old Ptch1þ/ mice. Importantly,
TUNEL labeling found that PERK heterozygous deﬁ-
ciency signiﬁcantly increased the number of apoptotic cells
in diffuse hyperplastic lesions in 6-week-old Ptch1þ/
mice (Figure 7, G, H, and L). Active-caspase 3 IHC also
found that the number of apoptotic cells were signiﬁcantly1946increased in diffuse hyperplastic lesions in 6-week-old
Ptch1þ/; Perkþ/ mice compared with Ptch1þ/; Perkþ/þ
mice (Figure 7, I, J, and M). However, there were
noticeably fewer active-caspase 3-positive cells than
TUNEL-positive cells in corresponding lesions. This
discrepant result likely reﬂects that TUNEL labeling is a
more sensitive method to detect cell apoptosis in diffuse
hyperplastic lesions than active-caspase 3 IHC. Collec-
tively, these data suggest that PERK haploinsufﬁciency
enhances premalignant GCP apoptosis in diffuse hyper-
plastic lesions in the cerebellum of Ptch1þ/ mice duringajp.amjpathol.org - The American Journal of Pathology
Figure 6 PERK heterozygous deﬁciency did not
reduce the number of the cerebellar hyperplastic
lesions in young Ptch1þ/ mice. A: The scatter
plot shows that PERK heterozygous deﬁciency did
not signiﬁcantly change the number of total hy-
perplastic lesions in the cerebellum of 6-week-old
Ptch1þ/ mice. B: The scatter plot shows that
PERK heterozygous deﬁciency did not reduce the
number of diffuse hyperplastic lesions in the cer-
ebellum of 6-week-old Ptch1þ/ mice. Data are
expressed as means  SD. n Z 10 mice. PERK,
pancreatic endoplasmic reticulum kinase.
PERK in Medulloblastoma Tumorigenesismalignant transformation of medulloblastoma. As described
in PERK Haploinsufﬁciency Reduces the Incidence of
Medulloblastomas in Ptch1þ/ Mice, we found that PERK
haploinsufﬁciency reduced the incidence of medulloblastoma
but had a minimal effect on tumor cells in adult Ptch1þ/
mice after malignant transformation. Taken together, our data
indicate that PERK haploinsufﬁciency suppresses medullo-
blastoma development in Ptch1þ/ mice by enhancing pre-
malignant GCP apoptosis in diffuse hyperplastic lesions
during the course of malignant transformation.
It was found that PERK activation attenuates the activity
of the p53 pathway, the master regulator of apoptosis during
malignant transformation.45,46 A previous report found that
p53 deﬁciency increases the incidence and accelerates the
development of medulloblastomas in Ptch1þ/ mice.47
Therefore, we were interested in the potential role of p53
in the proapoptotic effects of PERK haploinsufﬁciency on
premalignant GCPs. p53 Immunostaining found immuno-
reactivity of p53 was noticeably increased in diffuse hy-
perplastic lesions in 6-week-old Ptch1þ/; Perkþ/ mice
compared with Ptch1þ/; Perkþ/þmice (Figure 7, N and O).
PUMA, a Bcl-2 homology 3-only Bcl-2 family member, is a
p53-responsive gene and a critical mediator of p53-induced
apoptosis.48,49 Interestingly, PUMA immunostaining found
that immunoreactivity of PUMA was markedly elevated in
diffuse hyperplastic lesions in 6-week-old Ptch1þ/; Perkþ/
mice compared with Ptch1þ/; Perkþ/þ mice (Figure 7, P
and Q). Collectively, these data suggest the possibility that
PERK haploinsufﬁciency induces premalignant GCP
apoptosis in diffuse hyperplastic lesions during the course of
malignant transformation by increasing the activity of the
p53-PUMA pathway.
Discussion
With the use of in vitro and xenograft models, recent studies
suggest that PERK activation might promote malignancy by
attenuating apoptosis during the course of cell trans-
formation.13,43 Although two previous papers indicate the
inhibiting effects of PERK deﬁciency on tumor growth in
genetically engineered mouse models,50,51 the promoting
role of PERK signaling in malignant transformation has not
been veriﬁed in animal models that faithfully resemble
human tumors. Ptch1þ/ mice recapitulate human Gorlin’sThe American Journal of Pathology - ajp.amjpathol.orgsyndrome and are regarded as the best mouse model to
study the mechanisms of malignant transformation of the
SHH subgroup of medulloblastomas.21,23,24,44 With the use
of this mouse model, herein, we provided compelling evi-
dence that PERK activation promoted medulloblastoma
development by attenuating premalignant GCP apoptosis
during the course of malignant transformation. We showed
that PERK signaling was activated in premalignant GCP in
focal hyperplastic lesions and diffuse hyperplastic lesions in
the cerebellum of young Ptch1þ/ mice, in medulloblas-
toma cells in adult Ptch1þ/ mice, and in medulloblastoma
cells in human patients. We demonstrated that PERK hap-
loinsufﬁciency reduced the incidence of medulloblastomas
in Ptch1þ/ mice. Importantly, we found that PERK hap-
loinsufﬁciency had a minimal effect on medulloblastoma
cells in adult Ptch1þ/ mice after malignant transformation
but signiﬁcantly enhanced premalignant GCP apoptosis in
diffuse hyperplastic lesions in young Ptch1þ/ mice during
malignant transformation.
Apoptosis is believed to serve as a natural barrier to
malignancy.11,12 The transforming effects of oncogenes,
which drive unrestrained cell proliferation, are countered by
intrinsic apoptosis mechanisms, which are triggered in
response to various physiologic stresses that cells experi-
ence during the course of malignant transformation. Recent
studies report that ER stress is activated in cells during
malignant transformation and that PERK activation in
response to ER stress either facilitates the transformation by
suppressing apoptosis or impairs the transformation by
promoting apoptosis.13,15,43 In this study, we showed that
PERK signaling was activated in premalignant GCPs in
reversible hyperplastic lesions in the cerebellum of young
Ptch1þ/ mice and that PERK haploinsufﬁciency enhanced
premalignant GCP apoptosis and reduced tumor incidence
in these mice. Thus, our data suggest that PERK signaling
promotes medulloblastoma tumorigenesis by circumventing
apoptosis during the transformation of GCPs. It is generally
believed that activation of PERK signaling preserves cell
viability under stressful conditions through inhibition of
global protein biosynthesis and induction of certain stress-
induced cytoprotective genes.2,3 Several studies report that
PERK activation attenuates the activity of the p53 pathway,
the master regulator of apoptosis during malignant trans-
formation.45,46 Loss-of-function mutations of p53 contribute1947
Figure 7 PERK heterozygous deﬁciency enhanced apoptosis of premalignant GCPs in diffuse hyperplastic lesions in the cerebellum of young Ptch1þ/ mice. A:
H&E staining revealed a diffuse hyperplastic lesion (arrow) in the cerebellum of 6-week-old Ptch1þ/; Perkþ/þ mice. B: H&E staining revealed a diffuse hy-
perplastic lesion (arrow) in the cerebellum of 6-week-old Ptch1þ/; Perkþ/ mice. C and D: p-PERK IHC found noticeably decreased immunoreactivity of p-PERK in
diffuse hyperplastic lesions in 6-week-old Ptch1þ/; Perkþ/ mice compared with Ptch1þ/; Perkþ/þ mice. E, F, and K: BrdU labeling revealed comparable number
of proliferating cells in diffuse hyperplastic lesions in 6-week-old Ptch1þ/; Perkþ/þ mice and Ptch1þ/; Perkþ/ mice. G, H, and L: TUNEL staining revealed
signiﬁcantly increased number of apoptotic cells in diffuse hyperplastic lesions in 6-week-old Ptch1þ/; Perkþ/ mice compared with Ptch1þ/; Perkþ/þ mice. I,
J, and M: Active-caspase 3 IHC revealed signiﬁcantly increased number of apoptotic cells in diffuse hyperplastic lesions in 6-week-old Ptch1þ/; Perkþ/ mice
compared with Ptch1þ/; Perkþ/þ mice. N and O: p53 Immunostaining revealed noticeably increased expression of p53 in diffuse hyperplastic lesions in 6-week-
old Ptch1þ/; Perkþ/ mice compared with Ptch1þ/; Perkþ/þ mice. P and Q: PUMA immunostaining revealed noticeably increased expression of PUMA in diffuse
hyperplastic lesions in 6-week-old Ptch1þ/; Perkþ/ mice compared with Ptch1þ/; Perkþ/þ mice. Data are expressed as means SD. nZ 3 animals. *P < 0.05.
Scale bars: 1000 mm (A and B); 100 mm (C and D); 50 mm (EeJ); 32 mm (NeQ). BrdU, bromodeoxyuridine; GCP, granule cell precursor; H&E, hematoxylin and
eosin; IHC, immunohistochemistry; p-, phosphorylated; PERK, pancreatic endoplasmic reticulum kinase; PUMA, p53 up-regulated modulator of apoptosis; TUNEL,
terminal deoxynucleotidyl transferaseemediated biotinylated UTP nick end labeling.
Ho et alsigniﬁcantly to the tumorigenesis of many tumor types,
including medulloblastoma.11,12 Approximately 10% of
human medulloblastomas have mutations in p53.17,52 More-
over, p53 deﬁciency dramatically increases the incidence1948and accelerates the development of medulloblastomas in
Ptch1þ/ mice.47 Interestingly, we showed here that the
increased premalignant GCP apoptosis in diffuse hyperplastic
lesions of Ptch1þ/; Perkþ/ mice was accompanied with theajp.amjpathol.org - The American Journal of Pathology
PERK in Medulloblastoma Tumorigenesisenhanced expression of p53 and PUMA. Therefore, there is a
possibility that PERK signaling promotes medulloblastoma
tumorigenesis through attenuation of premalignant GCP
apoptosis by inhibiting the activity of the p53-PUMA
pathway.
The PERK-eIF2a pathway is a major regulator of cell
viability during ER stress under various physiologic and
pathologic conditions.2,3 As expected, we found that PERK
heterozygous deﬁciency signiﬁcantly attenuated the activity
of the PERK-eIF2a pathway in medulloblastoma cells in
adult Ptch1þ/ mice. Surprisingly, TUNEL labeling found
that PERK heterozygous deﬁciency had no signiﬁcant effect
on cell apoptosis in the tumor. Moreover, BrdU labeling and
PCNA immunostaining found that PERK heterozygous
deﬁciency did not alter cell proliferation in the tumor.
Multiple cooperative mutations of oncogenes and onco-
suppressor genes are necessary for tumorigenesis. It is
generally believed that additional mutations of oncogenes or
oncosuppressor genes, besides Ptch1 heterozygous muta-
tion, are required for medulloblastoma tumorigenesis in
Ptch1þ/ mice.23,44,53 The diminished impact of PERK
haploinsufﬁciency on medulloblastoma cell viability,
compared with its proapoptotic effect on premalignant
GCPs in diffuse hyperplastic lesions, suggests that the tumor
cells in Ptch1þ/; Perkþ/ mice gain additional mutations
or epigenetic changes that compensate or overcome the
deﬁciency of the PERK-eIF2a pathway.
Data from in vitro studies and xenograft models suggest
that PERK activation enhances tumor angiogenesis by
inducing VEGF-A expression.42,54 In vitro studies from
our laboratory and other groups found that PERK activa-
tion enhances VEGF-A expression in human medullo-
blastoma cells.26,55 Our previous study also suggests that
inactivation of GADD34, a regulatory subunit of a phos-
phatase complex that dephosphorylates eIF2a, enhances
the activity of the PERK-eIF2a pathway and may facilitate
medulloblastoma formation in the cerebellum of transgenic
mice that express the immune cytokine interferon-g in the
central nervous system by promoting angiogenesis through
induction of VEGF-A.29 Moreover, a report indicates that
PERK deﬁciency attenuates tumor cell proliferation and
angiogenesis in b-cell insulinomas in transgenic mice that
express the SV40 large T-antigen speciﬁcally in b cells.50
In contrast, another report indicates that PERK deﬁciency
delays tumor development but has no important effect on
angiogenesis in mammary adenocarcinoma in transgenic
mice that express oncogene Neu speciﬁcally in mammary
epithelium.51 We showed here that PERK hap-
loinsufﬁciency reduced the incidence of medulloblastomas
in Ptch1þ/ mice but did not affect VEGF-A expression or
angiogenesis in the tumor. Collectively, these data likely
suggest that the promoting effects of PERK signaling on
VEGF-A expression and/or tumor angiogenesis are not
ubiquitous, possibly determined by genetic mutations or
epigenetic changes in individual molecular subtypes of
tumors.The American Journal of Pathology - ajp.amjpathol.orgConclusions
With the use of Ptch1þ/ mice, the results presented in this
study suggest that PERK activation contributes to medul-
loblastoma development through inhibition of premalignant
GCP apoptosis during the course of malignant trans-
formation. This work represents the ﬁrst experimental
demonstration of a link between PERK activation and ma-
lignant transformation in an animal model that faithfully
resembles human tumor. Moreover, we demonstrated PERK
activation in human medulloblastoma. Unfortunately,
human samples do not afford an opportunity to study the
early stages of tumor development, but the persistence of
PERK signaling is also consistent with a pervasive role in
medulloblastoma tumorigenesis.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2016.03.004.References
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